Phillips Medisize Expands Inhalation Drug Delivery Expertise with Vectura

• Phillips Medisize, a global CDMO under Molex, has acquired Vectura Group Ltd., enhancing its inhalation drug delivery and pharmaceutical development capabilities.

• The acquisition brings proprietary technologies, expanded services, and approximately 350 new employees to Phillips Medisize’s global operations.

Phillips Medisize, a company designing and manufacturing innovative products for the pharmaceutical drug delivery, in vitro diagnostic and medtech markets, has finalised the acquisition of Vectura Group Ltd. from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International Inc. This strategic move further strengthens Phillips Medisize’s position as a contract development and manufacturing organisation (CDMO) with expanded capabilities in inhalation drug delivery and pharmaceutical R&D services.

The acquisition includes Vectura’s proprietary inhalation technologies such as dry powder inhalers (DPI), metered dose inhalers (MDI), and nebulizers, including the FOX™ device. These platforms, alongside Vectura’s formulation, process development, and regulatory services, will bolster Phillips Medisize’s ability to address growing global demand for inhalation therapies targeting chronic respiratory diseases like asthma and COPD, as well as non-respiratory conditions.

“Phillips Medisize will continue to expand the services we offer pharmaceutical companies thanks to the acquisition of Vectura, particularly in inhalation, to help meet growing patient needs,” said Paul Chaffin, President of Phillips Medisize.

With this acquisition, Phillips Medisize gains approximately 350 new employees, including scientists and engineers, further strengthening its global team of over 6,000 professionals across 30 sites and three continents. Vectura’s expertise will integrate seamlessly into Phillips Medisize’s end-to-end development capabilities, offering customers enhanced solutions for combination product development and manufacturing.

Joe Nelligan, CEO of Molex, stated, “The acquisition of Vectura reflects our commitment to advancing industry-leading medical capabilities for our customers. Together Phillips Medisize and Vectura will unlock significant growth potential to support the growing need for inhalation therapies.”